Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, Quiros-Roldan E, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, Gori A, Nasta P, Torti C; Italian MASTER Cohort. Lapadula G, et al. Among authors: di filippo e, di pietro m, di giambenedetto s. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):312-8. doi: 10.1097/QAI.0000000000000585. J Acquir Immune Defic Syndr. 2015. PMID: 25723139
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
Quiros-Roldan E, Raffetti E, Castelli F, Focà E, Castelnuovo F, Di Pietro M, Gagliardini R, Gori A, Saracino A, Fornabaio C, Sighinolfi L, Di Filippo E, Maggiolo F, Donato F. Quiros-Roldan E, et al. Among authors: di filippo e, di pietro m. J Antimicrob Chemother. 2016 Dec;71(12):3519-3527. doi: 10.1093/jac/dkw307. Epub 2016 Aug 19. J Antimicrob Chemother. 2016. PMID: 27543658
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C. Postorino MC, et al. Among authors: di filippo e, di pietro m. BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z. BMC Infect Dis. 2017. PMID: 28298195 Free PMC article.
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L, Mora S, Giacomini M, Gori A, Maggiolo F. Taramasso L, et al. Among authors: di filippo e, di biagio a. PLoS One. 2019 Oct 11;14(10):e0223181. doi: 10.1371/journal.pone.0223181. eCollection 2019. PLoS One. 2019. PMID: 31603906 Free PMC article.
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Among authors: di filippo e. J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. doi: 10.1093/jac/dkaa018. J Antimicrob Chemother. 2020. PMID: 32129855 Clinical Trial.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
73 results